Vcanbio Cell & Gene Engineering Corp., Ltd (SHA:600645)

Market Cap	14.53B +53.9%
Revenue (ttm)	1.47B -7.6%
Net Income	74.75M -30.4%
EPS	0.17 -29.6%
Shares Out	455.90M
PE Ratio	191.10
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	24,804,940
Average Volume	20,358,814
Open	30.30
Previous Close	30.77
Day's Range	30.18 - 32.88
52-Week Range	18.90 - 32.99
Beta	0.44
RSI	61.39
Earnings Date	Apr 25, 2026

About SHA:600645

Vcanbio Cell & Gene Engineering Corp., Ltd, together with its subsidiaries, engages in the preparation and storage of cell detection tests in the People’s Republic of China. It offers cell test preparation and storage services for umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, immune cells, adipose stem cells, and dental stem cells. The company also provides genetic testing services related to non-invasive prenatal genetic testing during pregnancy, genetic testing for drug...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1992
• Employees: 2,014
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600645

Financial Performance

In 2024, SHA:600645's revenue was 1.59 billion, a decrease of -0.27% compared to the previous year's 1.59 billion. Earnings were 100.35 million, a decrease of -5.73%.